In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 8, 2015, Pages 2041-2050

  Dwivedi, Anupma ^a   Mazumder, Anisha ^a   du Plessis, Lissinda ^a   du Preez, Jan L ^a   Haynes, Richard K ^a   du Plessis, Jeanetta ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Artemisone; Cytotoxic; Melanoma; Nano vesicles; Niosomes; Solid lipid nanoparticles (SLN)

Indexed keywords

BIOCHEMISTRY; CELLS; CYTOLOGY; CYTOTOXICITY; DISEASES; ENCAPSULATION; NANOPARTICLES; ONCOLOGY;

ARTEMISONE; CYTOTOXIC; MELANOMA; NANO-VESICLES; NIOSOMES; SOLID LIPID NANOPARTICLE (SLN);

DERMATOLOGY;

ARTEMISONE; NANOPARTICLE; NANOVESICULAR NIOSOME; NIOSOME; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; DRUG CARRIER; LIPID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BOWES MELANOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; MELANOMA CELL; NANOENCAPSULATION; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; MELANOMA; PATHOLOGY;

ANTIMALARIALS; ANTINEOPLASTIC AGENTS; ARTEMISININS; CELL LINE; CELL SURVIVAL; DRUG CARRIERS; HUMANS; LIPIDS; MELANOMA; NANOPARTICLES;

EID: 84951141990     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.07.010     Document Type: Article

References (38)

1. Manola J., Atkins M., Ibrahim J., Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000, 18(22):3782-3793.
2. Oppermann M., Geilen C.C., Fecker L.F., Gillissen B., Daniel P.T., Eberle J. Caspase independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk/Bik. Oncogene 2005, 24(49):7369-7380.
3. Leung A.M., Hari D.M., Morton D.L. Surgery for distant melanoma metastasis. Cancer J 2012, 18(2):176-184.
4. Antimalaria Coordinating Research Group Antimalaria studies on qinghaosu. Chin Med J 1979, 92(12):811-816.
5. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228:1049-1055.
6. Krishna S., Bustamante L., Haynes R.K., Staines H.M. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 2008, 29(10):520-527.
7. Woerdenbag H.J., Moskal T.A., Pras N. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J Nat Prod 1993, 56(6):849-856.
8. Reungpatthanaphong P., Mankhetkorn S. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 2002, 25(12):1555-1561.
9. Efferth T., Saverbrey A., Olbrich A. Molecular modes of action of artesunate in tumour cell lines. Mol Pharmacol 2003, 64(2):382-394.
10. Crespo-Ortiz M.P., Wei M.Q. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 2012, 2012:1-18.
11. Lai H.C., Singh N.P., Sasaki T. Development of artemisinin compounds for cancer treatment. Investig New Drugs 2013, 31(1):230-246.
12. Haynes R.K., Cheu K.W., N'Da D., Coghi P., Monti D. Considerations on the mechanism of action of artemisinin antimalarials: part 1-the 'carbon radical' and 'heme' hypotheses. Infect Disord Drug Targets 2013, 13(4):217-277.
13. Haynes R.K., Cheu K.W., Chan H.W., Wong H.N., Li K.Y., Tang M.M.K., et al. Interactions between artemisinins and other antimalarial drugs in relation to the co-factor model-a unifying proposal for drug action. ChemMedChem 2012, 7:2204-2226.
14. Ashton M., Sy N.D., Van H.N. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 1998, 63(4):482-493.
15. Li Q., Weina P.J., Milhous W.K. Pharmacokinetic and pharmacodynamic profiles of rapid-acting artemisinins in the antimalarial therapy. Curr Drug Ther 2007, 2(3):210-223.
16. Vivas L., Rattray L., Stewart L.B., Robinson B.L., Fugmann B., Haynes R.K., et al. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. J Antimicrob Chemother 2007, 59:658-665.
17. Haynes R.K., Fugmann B., Stetter J., Rieckmann K., Heilmann H., Chan H., et al. Artemisone-a highly active antimalarial drug of the artemisinin class. Angew Chem Int Ed 2006, 46:1989-2148.
18. Gravett A.M., Liu W.M., Krishna S., Chan W.C., Haynes R.K., Wilson N.L., et al. In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemother Pharmacol 2011, 67(3):569-577.
19. Schlupp P., Blaschke T., Kramer K.D., Höltje H.D., Mehnert W., Schäfer-Korting M. Drug release and skin penetration from solid lipid nanoparticles and a base cream: a systematic approach from a comparison of three glucocorticoids. Skin Pharmacol Physiol 2011, 24(4):199-209.
20. Sathali A.A.H., Rajalakshmi G. Evaluation of transdermal targeted niosomal drug delivery of terbinafine hydrochloride. Int J Pharm Technol Res 2010, 2(3):2081-2089.
21. Ruckmani K., Jayakar B., Ghosal S.K. Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage, and in vitro release. Drug Dev Ind Pharm 2000, 26(2):217-222.
22. Athawale R.B., Jain D.S., Singh K.K., Gude R.P. Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung. Biomed Pharmacother 2014, 68(2):231-240.
23. Dwivedi P., Khatik R., Khandelwal K., Taneja I., Kanumuri S.R.R., Wahajuddin, et al. Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm 2014, 466:321-327.
24. Aditya N.P., Chimote G., Gunalan K., Banerjee R., Patankar S., Madhusudhan B. Curcuminoids-loaded liposomes in combination with arteether protects against Plasmodium berghei infection in mice. Exp Parasitol J 2012, 131:292-299.
25. Asgharkhani E., Najmafshar A., Chiani M. Artemisinin (ART) drug deliveryusing mixed non-ionic surfactants and evaluation of their efficiency in different cancer cell lines. Int J Drug Deliv Technol 2014, 4(4):67-71.
26. Jain S., Jain S., Khare P., Gulbake A., Bansal D., Jain S.K. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Deliv 2010, 17(6):443-451.
27. Steyn J.D., Wiesner L., du Plessis L.H., Grobler A.F., Smith P.J., Chan W.C., et al. Absorption of the novel artemisinin derivatives artemisone and artemiside: potential application of Pheroid™ technology. Int J Pharm 2011, 414(1-2):260-266.
28. Grobler L., Grobler A., Haynes R., Masimirembwa C., Thelingwani R., Steenkamp P., et al. The effect of the Pheroid™ delivery system on the in vitro metabolism and in vivo pharmacokinetics of artemisone. Expert Opin Drug Metab Toxicol 2014, 10(3):313-325.
29. Wang S., Chen T., Chen R., Hu Y., Chen M., Wang Y. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm 2012, 430(1-2):238-246.
30. Yassin A.E.B., Anwer M.K., Mowafy H.A., El-Bagory I.M., Bayomi M.A., Alsarra I.A. Optimization of 5-fluorouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci 2010, 7:398-408.
31. Shenoy V., Gude R., Murthy R. In vitro anticancer evaluation of 5-fluorouracil lipid nanoparticles using B16F10 melanoma cell lines. Int Nano Lett 2013, 3(36):1-9.
32. Ruckmani K., Sankar V. Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech 2010, 11(3):1119-1127.
33. Das A.K. Anticancer effect of antimalarial artemisinin compounds. Ann Med Health Sci Res 2015, 5(2):93-102.
34. Waknine-Grinberg J.H., Hunt N., Bentura Marciano A., McQuillan J.A., Chan H.W., Chan W.C., et al. Artemisone effective against murine cerebral malaria. Malar J 2010, 9:227-239.
35. Wlodkowic D., Telford W., Skommer J., Darzynkiewicz Z. Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol 2011, 103:55-98.
36. Gupte A., Mumper R.J. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009, 35:32-46.
37. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov 2009, 8:579-591.
38. Gorrini C., Harris I.S., Mak T.W. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013, 12:931-947.